PMID- 32702097
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211204
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Print)
IS  - 2473-9529 (Linking)
VI  - 4
IP  - 14
DP  - 2020 Jul 28
TI  - High metabolic tumor volume is associated with decreased efficacy of axicabtagene 
      ciloleucel in large B-cell lymphoma.
PG  - 3268-3276
LID - 10.1182/bloodadvances.2020001900 [doi]
AB  - High metabolic tumor volume (MTV) predicts worse outcomes in lymphoma treated 
      with chemotherapy. However, it is unknown if this holds for patients treated with 
      axicabtagene ciloleucel (axi-cel), an anti-CD19 targeted chimeric antigen 
      receptor T-cell therapy. The primary objective of this retrospective study was to 
      investigate the relationship between MTV and survival (overall survival [OS] and 
      progression-free survival [PFS]) in patients with relapsed/refractory large 
      B-cell lymphoma (LBCL) treated with axi-cel. Secondary objectives included 
      finding the association of MTV with response rates and toxicity. The MTV values 
      on baseline positron emission tomography of 96 patients were calculated via 
      manual methodology using commercial software. Based on a median MTV cutoff value 
      of 147.5 mL in the first cohort (n = 48), patients were divided into high and low 
      MTV groups. Median follow-up for survivors was 24.98 months (range, 10.59-51.02 
      months). Patients with low MTV had significantly superior OS (hazard ratio [HR], 
      0.25; 95% confidence interval [CI], 0.10-0.66) and PFS (HR, 0.40; 95% CI, 
      0.18-0.89). Results were successfully validated in a second cohort of 48 patients 
      with a median follow-up for survivors of 12.03 months (range, 0.89-25.74 months). 
      Patients with low MTV were found to have superior OS (HR, 0.14; 95% CI, 
      0.05-0.42) and PFS (HR, 0.29; 95% CI, 0.12-0.69). In conclusion, baseline MTV is 
      associated with OS and PFS in axi-cel recipients with LBCL.
CI  - (c) 2020 by The American Society of Hematology.
FAU - Dean, Erin A
AU  - Dean EA
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer and Research Institute, 
      Tampa, FL.
FAU - Mhaskar, Rahul S
AU  - Mhaskar RS
AD  - Department of Internal Medicine, University of South Florida Morsani College of 
      Medicine, Tampa, FL.
FAU - Lu, Hong
AU  - Lu H
AD  - Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
FAU - Mousa, Mina S
AU  - Mousa MS
AD  - Department of Diagnostic Imaging and Interventional Radiology.
FAU - Krivenko, Gabriel S
AU  - Krivenko GS
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, and.
FAU - Lazaryan, Aleksandr
AU  - Lazaryan A
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, and.
FAU - Bachmeier, Christina A
AU  - Bachmeier CA
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, and.
AD  - Department of Pharmacy, H. Lee Moffitt Cancer and Research Institute, Tampa, FL.
FAU - Chavez, Julio C
AU  - Chavez JC
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer and Research Institute, 
      Tampa, FL.
FAU - Nishihori, Taiga
AU  - Nishihori T
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, and.
FAU - Davila, Marco L
AU  - Davila ML
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, and.
FAU - Khimani, Farhad
AU  - Khimani F
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, and.
FAU - Liu, Hien D
AU  - Liu HD
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, and.
FAU - Pinilla-Ibarz, Javier
AU  - Pinilla-Ibarz J
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer and Research Institute, 
      Tampa, FL.
FAU - Shah, Bijal D
AU  - Shah BD
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer and Research Institute, 
      Tampa, FL.
FAU - Jain, Michael D
AU  - Jain MD
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, and.
AD  - Department of Oncologic Sciences, University of South Florida Morsani School of 
      Medicine, Tampa, FL; and.
FAU - Balagurunathan, Yoganand
AU  - Balagurunathan Y
AD  - Department of Biostatistics and Bioinformatics, and.
FAU - Locke, Frederick L
AU  - Locke FL
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, and.
AD  - Immunology Program, H. Lee Moffitt Cancer and Research Institute, Tampa, FL.
LA  - eng
GR  - K23 CA201594/CA/NCI NIH HHS/United States
GR  - P30 CA076292/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
RN  - 0 (Antigens, CD19)
RN  - 0 (Biological Products)
RN  - U2I8T43Y7R (axicabtagene ciloleucel)
SB  - IM
MH  - *Antigens, CD19/therapeutic use
MH  - Biological Products
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Retrospective Studies
MH  - Tumor Burden
PMC - PMC7391155
COIS- Conflict-of-interest disclosure: C.A.B. is a scientific advisor to Kite/Gilead 
      and on the Novartis speaker bureau. J.C.C. is on the Kite/Gilead speaker bureau. 
      T.N. provides research support to Novartis (to Moffitt Cancer Center on clinical 
      trial support) and Karyopharm (to Moffitt Cancer Center on clinical trial 
      support). M.L.D. has stock options in Adaptiv Biotechnologies and Certainty 
      Therapeutics; personal fees in Servier, Glaxo Smith Kline, Celyad, and Kite; 
      personal fees and stock in Precision BioScience and Bellicium Pharmaceuticals; 
      and a CAR design patent with Atara Biotherapeutics. J.P.-I. is a consultant for 
      Janssen, Pharmacyclics, AbbVie, AstraZeneca, Takeda, and TEVA and speaker for 
      Janssen, AbbVie, and Takeda. B.D.S. receives personal fees from Celgene/Juno/BMS, 
      Adaptive, Novartis, Pharmacyclics, Spectrum/Acrotech, and AstraZeneca for 
      consultancy (<$5000/year); received grants from Jazz for an 
      investigator-initiated trial and Incyte for salary support for research 
      (<$5000/year); and received a grant and personal fees from Kite/Gilead for 
      consultancy (<$5000/year) and salary support for research (<$5000/year). M.D.J. 
      has consultancy/advisory roles with Kite/Gilead and Novartis. F.L.L. is a 
      compensated scientific advisor to Kite/Gilead, Novartis, BMS/Celgene, Calibr, 
      Wugen, GammaDelta Therapeutics, and Allogene and a consultant for Cellular 
      Biomedicine Group (with grant options), and his institution holds the following 
      patents: double-mutant survivin vaccine, CAR T cells with enhanced metabolic 
      fitness, methods of enhancing CAR T-cell therapies, and mathematical model of CAR 
      T evolution. The remaining authors declare no competing financial interests.
EDAT- 2020/07/24 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/07/23
CRDT- 2020/07/24 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/07/23 00:00 [pmc-release]
AID - S2473-9529(20)31550-0 [pii]
AID - 2020/ADV2020001900 [pii]
AID - 10.1182/bloodadvances.2020001900 [doi]
PST - ppublish
SO  - Blood Adv. 2020 Jul 28;4(14):3268-3276. doi: 10.1182/bloodadvances.2020001900.